Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
NCT03829449 · AKARI Therapeutics · PHASE3 · terminated · last registry update 2025-04-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The early termination of this study is a business decision, Akari have made the decision to close their global Phase III PNH program. The decision was not related to any efficacy, safety or clinical concerns regarding Coversin/rVA576.” | – | Registry record, AKARI Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against LTB4R2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-05Also stopped (terminated): AKARI Therapeutics, nomacopan (rVA576) (NCT04784455)
- 2025-05-15Results posted on the registry: AKARI Therapeutics, nomacopan (rVA576) (NCT04784455)
- 2025-04-10Also stopped (terminated): AKARI Therapeutics, rVA576 + rVA576 (NCT04037891)
- 2025-04-09Also stopped (withdrawn): AKARI Therapeutics, nomacopan (rVA576) (NCT05061771)
- 2025-02-27Results posted on the registry: AKARI Therapeutics, rVA576 + rVA576 (NCT04037891)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision